Venous access catheter-related thrombosis in patients with cancer

Gaddh, Manila; Antun, Ana G.; Yamada, Kazumichi; Gupta, Pooja; Tran, Ha Le Bao; Rassi, Fuad El; Khoury, H. Jean

doi:10.3109/10428194.2013.813503

Cited by 15 publications

(15 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although CVC has the advantages of safety and convenience, the complications of CVC represented by CVC-related thrombosis have also been reported ( 32 ). The incidence of PICC-related thrombosis is closely related to the type of central venous catheter ( 33 ). In addition, the incidence of TE is related to the thickness of the catheter; the thicker the central venous catheter, the higher the incidence of VTE, and the more serious the damage to the vascular epidermis ( 32 , 33 ).…”

Section: Discussionmentioning

confidence: 99%

A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy

et al. 2021

View full text Add to dashboard Cite

Purpose: The aims of this study were to develop and validate a novel nomogram to predict thromboembolism (TE) in gastric cancer (GC) patients receiving chemotherapy and to test its predictive ability.Methods: This retrospective study included 544 GC patients who received chemotherapy as the initial treatment at two medical centers. Among the 544 GC patients who received chemotherapy, 275 and 137 patients in the First Affiliated Hospital of Nanchang University from January 2014 to March 2019 were enrolled in the training cohort and the validation cohort, respectively. A total of 132 patients in the Beilun branch of the First Affiliated Hospital of Zhejiang University from January 2015 to August 2019 were enrolled in external validation cohorts. The nomogram was based on parameters determined by univariate and multivariate logistic analyses. The prediction performance of the nomogram was measured by the area under the receiver operating characteristic curve (AUROC), the calibration curve, and decision curve analysis (DCA). The applicability of the nomogram was internally and independently validated.Results: The predictors included the Eastern Cooperative Oncology Group Performance Status (ECOG), presence of an active cancer (AC), central venous catheter (CVC), and D-dimer levels. These risk factors are shown on the nomogram and verified. The nomogram demonstrated good discrimination and fine calibration with an AUROC of 0.875 (0.832 in internal validation and 0.807 in independent validation). The DCA revealed that the nomogram had a high clinical application value.Conclusions: We propose the nomogram for predicting TE in patients with GC receiving chemotherapy, which can help in making timely personalized clinical decisions for different risk populations.

show abstract

Section: Discussionmentioning

confidence: 99%

A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Other risk factors for VTE include the need of a central venous catheter and use of G-CSF in up to half of the patients 53 , 57 , 58 . Studies have shown that there is a 0.3% to 28% incidence of catheter related VTE in patients with cancer 57 . In addition, the use of G-CSF increases the risk of VTE by 1.69 (range: 1.09-2.64) 54 .…”

Section: Tolerabilitymentioning

confidence: 99%

From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer

et al. 2018

View full text Add to dashboard Cite

The current management of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) is based on systemic chemotherapy. The results of the MPACT and PRODIGE clinical trials have demonstrated that the combination of nab-paclitaxel and gemcitabine (GEM) as well as FOLFIRINOX regimen result in improvement in overall survival when compared to GEM alone. Treatment guidelines now recommend either one of these two regimens as first line treatment for fit patients with mPDAC. Because no head-to-head comparison between the two regimens exists, the selection of one versus the other is based on clinical criteria. The design and eligibility criteria of these two clinical trials are dissimilar, making the results of the MPACT trial more applicable to the general population of patients with mPDAC. In addition, the combination of nab-paclitaxel and GEM is better tolerated and easier to administer in clinical practice than FOLFIRINOX. Furthermore, when the regimens are studied in comparable patient populations the efficacy results are very similar. Nanoliposomal irinotecan plus 5FU has recently demonstrated a significant increase in efficacy rates after a GEM-based treatment. Importantly, treatment of mPDAC should now be considered as a continuum care for patients who are fit, with second and even third line treatments. Different sequential treatment algorithms are proposed based on available data. In retrospective studies, patients who were managed with GEM-based regimens followed by fluoropyrimidine-based regimens appear to have the most favorable outcome.

show abstract

“…Kateterle ilişkili tromboz sıklığı uygulanan kateterin türüne, kateterin yerleştirildiği damara, kanser türüne ve uygulanan kanser tedavisine göre değişkenlik gösterir (43). Rehberler kateter seçiminde hasta özelliklerinin, uygulanacak kemoterapi türünün ve süresinin öncelikle göz önünde bulundurulmasını önermektedir.…”

Section: Kateterizasyonunclassified

Venous thromboembolism and cancer

Okutan

Ayten²

2014

Tuberk Toraks

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is one of the complications which have significant influence on mortality in patient with cancer. Early mortality rate is high in cancer patients who have VTE. This complication is related with cell type and stage of the cancer, surgery applied during cancer treatment, applying catheter and the chemotherapeutic agents. VTE prophylaxis and/or treatment in treatment and follow-up of cancer patients will provide a reduction in mortality and morbidity rates. VTE prophylaxis and treatment poses differences according to both treatment approaches which will be applied and the type of cancer. It has been aimed to describe pathogenesis, risk factors and treatment approaches taking into account international consensus reports in this review.

show abstract

Venous access catheter-related thrombosis in patients with cancer

Cited by 15 publications

References 94 publications

A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy

A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy

From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer

Venous thromboembolism and cancer

Contact Info

Product

Resources

About